Maple-bark-stripper's lung
ICD-10 J67.6 is a billable code used to indicate a diagnosis of maple-bark-stripper's lung.
Maple-bark-stripper's lung is a form of hypersensitivity pneumonitis, primarily affecting individuals exposed to organic dust, particularly those working with maple bark. Clinically, it presents with symptoms such as cough, dyspnea, and chest tightness, which may develop acutely or chronically depending on the duration and intensity of exposure. The condition arises from an immune response to inhaled antigens, leading to inflammation of the lung interstitium. Anatomically, the disease affects the alveoli and surrounding lung tissue, resulting in impaired gas exchange. Disease progression can lead to pulmonary fibrosis if exposure continues, causing long-term respiratory impairment. Diagnostic considerations include a thorough occupational history, clinical evaluation, imaging studies such as chest X-rays or CT scans, and pulmonary function tests to assess lung capacity and function. Serological tests may also be employed to identify specific antibodies related to the exposure. Early diagnosis and intervention are crucial to prevent irreversible lung damage.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
J67.6 specifically covers hypersensitivity pneumonitis due to exposure to maple bark and related organic dust. It is characterized by an immune response leading to lung inflammation and requires a detailed occupational history for diagnosis.
J67.6 should be used when the diagnosis is specifically linked to exposure to maple bark. If the hypersensitivity pneumonitis is due to other organic materials, other specific codes should be utilized.
Documentation should include a detailed occupational history, clinical symptoms, results from imaging studies, pulmonary function tests, and any serological tests performed to confirm hypersensitivity.
